DELRIN 4D trademark for medical syringes

USPTO received trademark application TM99532413 for "DELRIN 4D" filed December 5, 2025, under Intent-to-Use basis. The application covers syringes for injections, syringes for medical purposes, and medical patient training devices (needle-free syringes). This is a routine trademark filing in Class 10 (medical devices) with no final registration yet issued.

YMACA ROOTS Trademark Application for Medical Devices and Therapy Equipment

The USPTO received an Intent-to-Use trademark application (TM99520608) for YMACA ROOTS covering 82 goods and services categories spanning medical devices, therapy equipment, massage apparatus, diagnostic instruments, and personal care products. The application was filed on November 28, 2025, with a stated intent-to-use date of March 30, 2026. This filing establishes a priority date for the applicant's trademark claims in Class 10 (Medical Devices).

Alphacyte trademark medical imaging, diagnostic instruments

Alphacyte trademark medical imaging, diagnostic instruments

Administrative Monetary Penalty on BKRM for Cybersecurity and Customer Information Breaches

Bank Negara Malaysia imposed a RM1,000,000 Administrative Monetary Penalty on Bank Kerjasama Rakyat Malaysia Berhad (BKRM) for failing to implement robust cybersecurity standards under the Risk Management in Technology Policy Document and inadequate safeguards for customer information under the Management of Customer Information and Permitted Disclosures Policy Document. The breaches followed a cybersecurity incident where an external threat actor gained unauthorized access to BKRM's IT infrastructure.

ADHD Health Education & Advocacy Trademark Registration

The USPTO received trademark application TM98753172 for 'POWER AHEAD ADHD HEALTH, EDUCATION & ADVOCACY DIALOGUE' filed by POWER AHEAD LLC. The application covers downloadable software, educational media, online healthcare information, seminars, and public advocacy services related to ADHD management. The application was filed September 16, 2024, as an Intent-to-Use filing.

Neuropharmagen trademark for pharmacogenetics SAAS platform

USPTO received trademark application TM98671767 for NEUROPHARMAGEN filed by an unspecified applicant on July 29, 2024. The application covers International Class 044 medical services including pharmacogenetic analysis software (SAAS/PAAS), genetic testing and research services, medical diagnostic services, and clinical trial support. The application is filed on an Intent-to-Use basis with a deadline of March 31, 2026.

Health Elevation 360 Trademark Application - Class 44 Health Services

USPTO received trademark application TM98635213 for 'HEALTH ELEVATION 360' covering health, nutrition, and wellness counseling services (Class 44) along with athletic apparel and hair care products. The application was filed on July 5, 2024, under Intent to Use provisions with an extension deadline of March 31, 2026.

PSYCHIATRY DECONSTRUCTED Trademark Renewal

The USPTO renewed trademark registration TM98471657 for PSYCHIATRY DECONSTRUCTED on March 31, 2026. The mark covers medical services including psychiatric consultation, psychological consultation, and healthcare education information. The original application was filed March 27, 2024.

Playhouse Speech Therapy Trademark Renewal

USPTO renewed trademark TM98428511 for Playhouse Speech Therapy on March 31, 2026, extending trademark protection for speech therapy services. This is a routine administrative renewal with no new obligations or policy changes imposed on trademark holders.

Coalition Urges Congress to Pass Combating Xylazine Act

West Virginia Attorney General JB McCuskey joined a bipartisan coalition of 41 attorneys general in urging Congress to pass the Combating Xylazine Act. The proposed legislation would classify xylazine under Schedule III of the federal Controlled Substances Act and authorize the DEA to track manufacturing of the drug. Xylazine, a veterinary tranquilizer frequently combined with fentanyl, has contributed to increasing overdose deaths and complicates rescue efforts due to reduced naloxone efficacy.